<DOC>
	<DOC>NCT01237678</DOC>
	<brief_summary>The purpose of this study is to test safety and efficacy of this combination treatment (IMGN901, carboplatin and etoposide) in patients with solid tumors and extensive stage small cell lung cancer.</brief_summary>
	<brief_title>A Study to Test Safety and Efficacy of IMGN901 in Combination With Carboplatin/Etoposide in Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Ado-trastuzumab emtansine</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Maytansine</mesh_term>
	<criteria>Patients must be 18 years old Patients must have been diagnosed with smallcell lung cancer (SCLC) and extensive disease ECOG performance status of 0, 1, or 2 No prior systemic chemotherapy for the treatment of SCLC Pregnant or lactating females</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Immunogen</keyword>
	<keyword>Lung</keyword>
	<keyword>Small Cell Lung Cancer</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>ADC</keyword>
</DOC>